Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) EBIT (2023 - 2025)

Monte Rosa Therapeutics' EBIT history spans 3 years, with the latest figure at -$49.7 million for Q4 2025.

  • For Q4 2025, EBIT fell 162.62% year-over-year to -$49.7 million; the TTM value through Dec 2025 reached -$54.2 million, down 268.09%, while the annual FY2025 figure was -$54.2 million, 268.09% down from the prior year.
  • EBIT reached -$49.7 million in Q4 2025 per GLUE's latest filing, down from -$33.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $79.4 million in Q4 2024 to a low of -$49.7 million in Q4 2025.
  • Average EBIT over 3 years is -$17.7 million, with a median of -$33.6 million recorded in 2023.
  • Peak YoY movement for EBIT: skyrocketed 327.72% in 2024, then crashed 162.62% in 2025.
  • A 3-year view of EBIT shows it stood at -$34.9 million in 2023, then surged by 327.72% to $79.4 million in 2024, then plummeted by 162.62% to -$49.7 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's EBIT are -$49.7 million (Q4 2025), -$33.0 million (Q3 2025), and -$15.6 million (Q2 2025).